Trial Profile
An Open Label, Multi-centre, Phase I/II Dose Escalation Trial of a Recombinant Adeno-associated Virus Vector (AAV2-.RPGR) for Gene Therapy of Adults and Children With X-linked Retinitis Pigmentosa Owing to Defects in Retinitis Pigmentosa GTPase Regulator (RPGR)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Botaretigene sparoparvovec (Primary)
- Indications Retinitis pigmentosa
- Focus Adverse reactions; First in man
- Sponsors MeiraGTx
- 21 Apr 2023 According to Janssen media release, updates from this study will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting.
- 01 Oct 2022 Results published in the MeiraGTx Holdings Media Release.
- 01 Oct 2022 According to Janssen media release, data from this study were presented at the Retina Subspecialty Day program of the American Academy of Ophthalmology (AAO) 2022 Annual Meeting